VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Baidu, Inc. vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Baidu, Inc.
9888 · The Stock Exchange of Hong Kong Limited
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Baidu, Inc.'s moat claims, evidence, and risks.
View 9888 analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score: both at 71 / 100.
- Segment focus: Baidu, Inc. has 4 segments (54.5% in Online Marketing (Search & Feed Ads)); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Baidu, Inc. has 10 moat types across 4 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Baidu, Inc.
Online Marketing (Search & Feed Ads)
Chinese-language search and feed-based online marketing services
Mainland China
Advertisers (SMEs and larger enterprises) buying performance-based and feed ads
Search + feed platform operator / ad marketplace
54.5%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Baidu, Inc. strengths
AstraZeneca PLC strengths
Segment mix
Baidu, Inc. segments
Full profile >Online Marketing (Search & Feed Ads)
Quasi-Monopoly
AI Cloud (IaaS/PaaS/SaaS + GenAI APIs)
Oligopoly
Intelligent Driving & Other Growth Initiatives
Oligopoly
iQIYI (Online Entertainment)
Oligopoly
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.